Recent News

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases.

Peptimmune announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's PI-2301 for the treatment of multiple sclerosis.

Peptimmune announces first patient dosed in a phase Ib study of PI-2301 in multiple sclerosis patients in one of the most comprehensive studies of the pharmacologic effects of an immunomodulatory compound in autoimmune disease.

Peptimmune presented early clinical results from its PI-2301 peptide copolymer program at both the 17th Annual ENS meeting in Nice, France and at FOCIS 2008 in Boston, MA. The Company presented clinical data which demonstrated that all doses of PI-2301 were safe and well tolerated, and demonstrated early immunological effects consistent with its pharmacologic mechanism of action. Also presented were data detailing significant differences in the bioavailability, mechanism of action, and pharmacodynamic effects between PI-2301 and Copaxone® (Teva Pharmaceuticals).

We've completed our first clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases